Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23074
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBeyer, Leonie-
dc.contributor.authorNitschmann, Alexander-
dc.contributor.authorBarthel, Henryk-
dc.contributor.authorvan Eimeren, Thilo-
dc.contributor.authorUnterrainer, Marcus-
dc.contributor.authorSauerbeck, Julia-
dc.contributor.authorMarek, Ken-
dc.contributor.authorSong, Mengmeng-
dc.contributor.authorPalleis, Carla-
dc.contributor.authorRespondek, Gesine-
dc.contributor.authorHammes, Jochen-
dc.contributor.authorBarbe, Michael T-
dc.contributor.authorOnur, Özgür-
dc.contributor.authorJessen, Frank-
dc.contributor.authorSaur, Dorothee-
dc.contributor.authorSchroeter, Matthias L-
dc.contributor.authorRumpf, Jost-Julian-
dc.contributor.authorRullmann, Michael-
dc.contributor.authorSchildan, Andreas-
dc.contributor.authorPatt, Marianne-
dc.contributor.authorNeumaier, Bernd-
dc.contributor.authorBarret, Olivier-
dc.contributor.authorMadonia, Jennifer-
dc.contributor.authorRussell, David S-
dc.contributor.authorStephens, Andrew W-
dc.contributor.authorRoeber, Sigrun-
dc.contributor.authorHerms, Jochen-
dc.contributor.authorBötzel, Kai-
dc.contributor.authorLevin, Johannes-
dc.contributor.authorClassen, Joseph-
dc.contributor.authorHöglinger, Günter U-
dc.contributor.authorBartenstein, Peter-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorDrzezga, Alexander-
dc.contributor.authorSeibyl, John-
dc.contributor.authorSabri, Osama-
dc.contributor.authorBrendel, Matthias-
dc.date2020-04-21-
dc.date.accessioned2020-04-28T23:20:03Z-
dc.date.available2020-04-28T23:20:03Z-
dc.date.issued2020-04-21-
dc.identifier.citationEuropean journal of nuclear medicine and molecular imaging 2020; online first: 21 Aprilen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23074-
dc.description.abstractSecond-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG). Twenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, multi-system atrophy, Parkinson's disease, multi-system atrophy, Parkinson's disease, frontotemporal dementia) and received a dynamic [18F]PI-2620 tau-PET (0-60 min p.i.) and static [18F]FDG-PET (30-50 min p.i.). Regional standardized uptake value ratios of early-phase images (single frame SUVr) and the blood flow estimate (R1) of [18F]PI-2620-PET were correlated with corresponding quantification of [18F]FDG-PET (global mean/cerebellar normalization). Reduced tracer uptake in cortical target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three more and three less experienced readers. Spearman rank correlation coefficients were calculated between early-phase [18F]PI-2620 tau-PET and [18F]FDG-PET images for all cortical regions and frequencies of disagreement between images were compared for both more and less experienced readers. Highest agreement with [18F]FDG-PET quantification was reached for [18F]PI-2620-PET acquisition from 0.5 to 2.5 min p.i. for global mean (lowest R = 0.69) and cerebellar scaling (lowest R = 0.63). Correlation coefficients (summed 0.5-2.5 min SUVr & R1) displayed strong agreement in all cortical target regions for global mean (RSUVr 0.76, RR1 = 0.77) and cerebellar normalization (RSUVr 0.68, RR1 = 0.68). Visual interpretation revealed high regional correlations between early-phase tau-PET and [18F]FDG-PET. There were no relevant differences between more and less experienced readers. Early-phase imaging of [18F]PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a dual time-point protocol for tau-PET imaging could supersede additional [18F]FDG-PET imaging by indexing both the distribution of tau and the extent of neuronal injury.en
dc.language.isoeng-
dc.subjectNeuronal injuryen
dc.subjectPETen
dc.subjectPerfusionen
dc.subjectTauen
dc.subject[18F]PI-2620en
dc.titleEarly-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of nuclear medicine and molecular imagingen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germanyen
dc.identifier.affiliationMolecular Neuroimaging, inviCRO, New Haven, CT, USAen
dc.identifier.affiliationMax- Planck-Institute of Human Cognitive and Brain Sciences, Leipzig, Germanyen
dc.identifier.affiliationGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germanyen
dc.identifier.affiliationDepartment of Psychiatry, University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationCenter for Memory Disorders, University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationCognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Research Centre Juelich, Juelich, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationDepartment of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germanyen
dc.identifier.affiliationMunich Cluster for Systems Neurology (SyNergy), Munich, Germanyen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Technische Universität München, Munich, Germanyen
dc.identifier.affiliationDepartment of Neurology, Hannover Medical School, Hannover, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germanyen
dc.identifier.affiliationDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germanyen
dc.identifier.affiliationGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germanyen
dc.identifier.affiliationCenter for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germanyen
dc.identifier.affiliationInviCRO, LLC, Boston, MA, USAen
dc.identifier.affiliationInstitute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Juelich GmbH, Juelich, Germanyen
dc.identifier.affiliationInstitute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne, Germanyen
dc.identifier.affiliationClinic for Cognitive Neurology, University of Leipzig, Leipzig, Germanyen
dc.identifier.affiliationLIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germanyen
dc.identifier.affiliationDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationDepartment of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationDepartment of Neurology, University of Leipzig Medical Center, Leipzig, Germanyen
dc.identifier.affiliationCenter for Memory Disorders, University Hospital Cologne, Cologne, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germanyen
dc.identifier.affiliationLife Molecular Imaging GmbH, Berlin, Germanyen
dc.identifier.affiliationCenter for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germanyen
dc.identifier.affiliationDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germanyen
dc.identifier.affiliationDepartment of Neurology, University of Leipzig Medical Center, Leipzig, Germanyen
dc.identifier.affiliationDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germanyen
dc.identifier.doi10.1007/s00259-020-04788-wen
dc.type.contentTexten
dc.identifier.orcid0000-0002-5832-9875en
dc.identifier.pubmedid32318783-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 21, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.